Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia
NCT ID: NCT06979141
Last Updated: 2025-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
300 participants
INTERVENTIONAL
2025-06-02
2026-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intratracheal Dexmedetomidine Versus Lidocaine in Eye Surgery
NCT05291221
Magnesium Sulfate Versus Lidocaine as Additives to Dexmedetomidine for Cough Suppression After Functional Endoscopic Sinus Surgery
NCT07213037
Block Pressor Response to Intubation
NCT05659212
Dexmedetomidine Versus Ketamine-midazolam Sedation in Awake Fiberoptic Intubation in Suspected Difficult Airway
NCT06946212
Effect of Intratracheal Dexmedetomidine Administration on Recovery From General Anesthesia in Pediatrics Undergoing Lower Abdominal Surgery:
NCT04385602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexmedetomidine group ( D group )
Patients will receive 0.5 μg/kg dexmedetomidine in 10 ml normal saline 10 min before the end of surgery.
Dexmedetomidine
Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.
Magnesium sulfate group ( M group )
Patients will receive 30 mg/kg IV magnesium sulfate 50% in 10 ml normal saline 10 min before the end of surgery.
Magnesium sulfate
Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.
Lidocaine group ( L group )
Patients will receive lidocaine 1.5 mg/kg lidocaine in 10 ml normal saline 10 min before the end of surgery.
Lidocaine
Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.
Control group ( C group )
Patients will receive 10 ml normal saline 10 min before the end of surgery.
normal saline
Patients will receive 10 ml normal saline 10 min before the end of surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.
Magnesium sulfate
Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.
Lidocaine
Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.
normal saline
Patients will receive 10 ml normal saline 10 min before the end of surgery.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both genders.
* Body mass index \< 30 kg/ m2
* American Society of Anesthesiology (ASA) physical status I-II.
* Mallampati score class I or II.
* Patients undergoing surgery under general anesthesia.
Exclusion Criteria
* History of psychiatric illness.
* Patients with major organ diseases.
* Pre-existing neurological deficits.
* Body mass index \>30 kg/m2.
* Active airway infection or history of tracheal and laryngeal surgery.
* Lower esophageal sphincter incompetence (and reflux).
* Increased intracranial and intraocular pressure.
* Use of cough-inducing medications
* Pregnant, and lactating women.
21 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Al-Azhar University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mahmoud Talaat Abd Elhafeez Ahmed
Specialist. Mcs
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Al-Azhar university Assiut, Egypt.
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD/AZ.AST./AIP029/7/240/2/2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.